Though higher PCSK9 levels support the rationale for exploring anti-PCSK9 therapy as an option in patients with autoimmune liver diseases at risk for DILI, this warrants further preclinical and clinical investigations. Here, PCSK9 is linked to autoimmune hepatitis.